Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
pregabalin + celecoxib
- Development stage
- Phase 4
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Pregabalin + celecoxib is a fixed-dose combination of two small molecule drugs used primarily for the management of pain, particularly in conditions involving both neuropathic and nociceptive mechanisms such as chronic low-back pain, acute postoperative pain, and lumbar disc herniation. Pregabalin is an anticonvulsant that binds to the alpha2-delta subunit of presynaptic voltage-gated calcium channels in the central nervous system, thereby reducing the release of excitatory neurotransmitters like glutamate, norepinephrine, substance P, and dopamine. Celecoxib is a selective cyclooxygenase-2 (COX-2) inhibitor that reduces inflammation and pain by inhibiting prostaglandin synthesis. The combination has demonstrated superior analgesic efficacy compared to either drug alone and can reduce opioid requirements postoperatively with similar rates of adverse effects as monotherapy[1][2][4][7].
- Brand names
- Libroxar
- Other names
- celecoxib and pregabalinpreemptive celecoxib and pregabalin
02
Targets
PTGS2 (Prostaglandin-Endoperoxide Synthase 2)CACNA2D1 (Voltage-gated calcium channel subunit alpha2/delta-1)
Beyond the preview
Go deeper on pregabalin + celecoxib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on pregabalin + celecoxib.